Factor XIII activity mediates red blood cell retention in venous thrombi

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3590-3600

  Aleman, Maria M ^a   Byrnes, James R ^a   Wang, Jian Guo ^a   Tran, Reginald ^b   Lam, Wilbur A ^b   Paola, Jorge Di ^c   Mackman, Nigel ^a   Degen, Jay L ^d   Flick, Matthew J ^d   Wolberg, Alisa S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Emory University   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; FIBRINOGEN GAMMA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 13A; MUTANT PROTEIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVITY; ERYTHROCYTE; FIBRIN CLOT; FIBRIN DEPOSITION; GENE MUTATION; HEMOSTASIS; HOMOZYGOSITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VEIN THROMBOSIS; ANIMAL; BLOOD; BLOOD CLOTTING FACTOR 13 DEFICIENCY; C57BL MOUSE; DISEASE MODEL; GENETICS; HOMOZYGOTE; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PATHOLOGY;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; ERYTHROCYTES; FACTOR XIII; FACTOR XIII DEFICIENCY; FACTOR XIIIA; FIBRINOGEN; HOMOZYGOTE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MUTANT PROTEINS; MUTATION; PEPTIDE FRAGMENTS; VENOUS THROMBOSIS;

EID: 84905453345     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75386     Document Type: Article

References (61)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
2. Liu W, et al. Fibrin fibers have extraordinary extensibility and elasticity. Science. 2006;313(5787):634.
3. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:11-30.
4. Flick MJ, et al. Leukocyte engagement of fibrin (ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113(11):1596-1606.
5. Adams RA, et al. The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 2007;204(3):571-582.
6. Davalos D, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. 2012;3:1227.
7. Flick MJ, et al. Fibrin (ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin αMβ2 binding motif. J Clin Invest. 2007;117(11):3224-3235.
8. Steinbrecher KA, et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin αMβ2 engagement of fibrinogen. Cancer Res. 2010;70(7):2634-2643.
9. Vidal B, et al. Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the αMβ2 leukocyte integrin receptor. Hum Mol Genet. 2012;21(9):1989- 2004.
10. Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry. 1974;13(4):750-756.
11. Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb Haemost. 2007;97(6):890-898.
12. Lorand L, et al. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Commun. 1974;56(4):914-922.
13. Curtis CG, et al. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 1974;13(18):3774-3780.
14. Hornyak TJ, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry. 1991;30(25):6175-6182.
15. Greenberg CS, Shuman MA. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem. 1982;257(11):6096-6101.
16. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost. 2009;35(4):426-438.
17. Varma MR, et al. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg. 2003;38(5):1090-1098.
18. Day SM, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105(1):192-198.
19. Brill A, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117(4):1400-1407.
20. von Bruhl ML, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835.
21. Lu H, et al. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. J Clin Invest. 1997;99(6):1340-1350.
22. Hermand P, et al. Red cell ICAM-4 is a novel ligand for platelet-activated αIIbβ 3 integrin. J Biol Chem. 2003;278(7):4892-4898.
23. Goel MS, Diamond SL. Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma. Blood. 2002;100(10):3797-3803.
24. Souri M, Koseki-Kuno S, Takeda N, Degen JL, Ichinose A. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol. 2008;87(1):60-68.
25. Hanna M. Congenital deficiency of factor 13: report of a family from Newfoundland with associated mild deficiency of factor XII. Pediatrics. 1970;46(4):611-619.
26. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost. 2002;28(suppl 2):3-13.
27. Go AS, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
28. Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med. 2005;118(5):456-464.
29. Cines DB, et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood. 2014;123(10):1596-1603.
30. Leidy EM, Stern AM, Friedman PA, Bush LR. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb Res. 1990;59(1):15-26.
31. Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood. 1990;75(7):1455-1459.
32. Levy JH, Greenberg C. Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion. 2013;53(5):1120-1131.
33. Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, Peyvandi F. Factor XIII - an under diagnosed deficiency - are we using the right assays? J Thromb Haemost. 2010;8(11):2478-2482.
34. Smith KA, et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood. 2011;117(12):3460-3468.
35. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. 1996;35(32):10448-10453.
36. Gersh KC, Lord ST. An investigation of Factor XIII binding to recombinant γ./γ' and γ/γ' fibrinogen. Blood. 2006;108:485a.
37. Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin fiber in a clot. Proc Natl Acad Sci U S A. 2005;102(26):9133-9137.
38. Hethershaw EL, et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost. 2014;12(2):197-205.
39. Helms CC, Ariens RA, Uitte de Willige S, Standeven KF, Guthold M. α-α Cross-links increase fibrin fiber elasticity and stiffness. Biophys J. 2012;102(1):168-175.
40. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311.
41. Nikolajsen CL, Dyrlund TF, Toftgaard Poulsen E, Enghild JJ, Scavenius C. Coagulation Factor XIIIa substrates in human plasma. identification and incorporation into the clot. J Biol Chem. 2014;289(10):6526-6534.
42. Bereczky Z, Muszbek L. Factor XIII and venous thromboembolism. Semin Thromb Hemost. 2011;37(3):305-314.
43. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96(3):988-995.
44. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet. 2003;361(9367):1424-1431.
45. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol. 1999;6(2):76-82.
46. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008;13(suppl 3):11-15.
47. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290.
48. Small M, Lowe GD, Forbes CD, Thomson JA. Thromboembolic complications in Cushing's syndrome. Clin Endocrinol (Oxf). 1983;19(4):503-511.
49. Valeri CR, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001;41(8):977-983.
50. Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol. 1994;86(2):347-350.
51. Ho CH. The hemostatic effect of packed red cell transfusion in patients with anemia. Transfusion. 1998;38(11-12):1011-1014.
52. Ho CH. Increase of red blood cells can shorten the bleeding time in patients with iron deficiency anemia. Blood. 1998;91(3):1094.
53. Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost. 1999;81(3):400-406.
54. Horne MK, Horne MK 3rd, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol. 2006;133(4):403-408.
55. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012;120(18):3837-3845.
56. Wohner N, et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol. 2011;31(10):2306-2313.
57. Saha P, et al. Magnetic resonance T1 relaxation time of venous thrombus is determined by iron processing and predicts susceptibility to lysis. Circulation. 2013;128(7):729-736.
58. Henke PK, et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol. 2004;24(6):1130-1137.
59. Aleman MM, et al. Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol. 2013;33(8):1829-1836.
60. Dargaud Y, Spronk HM, Leenders P, Hemker HC, Ten Cate H. Monitoring platelet dependent thrombin generation in mice. Thromb Res. 2010;126(5):436-441.
61. Candiano G, et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis. 2004;25(9):1327-1333.